BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2103961)

  • 1. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.
    Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G
    Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
    Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum thymidine kinase in multiple myeloma: I. Relation to selected laboratory indicators in the disease].
    Scudla V; Bacovský J; Papajík T; Budíková M; Srovnalík K
    Vnitr Lek; 1994 Mar; 40(3):151-6. PubMed ID: 8184566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
    Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
    Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
    Greipp PR; Lust JA; O'Fallon WM; Katzmann JA; Witzig TE; Kyle RA
    Blood; 1993 Jun; 81(12):3382-7. PubMed ID: 8507875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum thymidine kinase in multiple myeloma: II. Relation to disease activity and stage].
    Scudla V; Papajík T; Bacovský J; Budíková M; Klímová D
    Vnitr Lek; 1994 Mar; 40(3):157-62. PubMed ID: 8184567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between tumor proliferation and serum levels of beta 2-microglobulin and thymidine kinase in malignant lymphomas.
    Lehtinen T
    Cancer Detect Prev; 1988; 12(1-6):125-31. PubMed ID: 3052829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myeloma.
    Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):3021-4. PubMed ID: 9329591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes of serum thymidine kinase in children with acute leukemia.
    Votava T; Topolcan O; Holubec L; Cerna Z; Sasek L; Finek J; Kormunda S
    Anticancer Res; 2007; 27(4A):1925-8. PubMed ID: 17649797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
    Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
    Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
    Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD
    Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum ferritin and beta-2-microglobulin in multiple myeloma].
    Linkesch W; Ludwig H
    Acta Med Austriaca; 1982; 9(5-6):227-31. PubMed ID: 6187172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase.
    Diem H; Fateh-Moghadam A; Lamerz R
    Clin Investig; 1993 Nov; 71(11):918-23. PubMed ID: 8312685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels.
    Scudla V; Budíková M; Fischerová E; Zadrazil J; Indrák K
    Acta Univ Palacki Olomuc Fac Med; 1991; 130():201-12. PubMed ID: 1838869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical usefulness of serum beta2-microglobulin determination in patients with multiple myeloma].
    Kraj M; Maj S; Pogłód R; Rostkowska J
    Acta Haematol Pol; 1989; 20(2):140-51. PubMed ID: 2700533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum ferritin and beta 2-microglobulin in patients with multiple myeloma.
    Linkesch W; Ludwig H
    Cancer Detect Prev; 1983; 6(1-2):297-301. PubMed ID: 6192921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic significance of beta-2-microglobulin in multiple myeloma].
    Podol'tseva EI; Morozova EV; Almazov VA
    Vopr Onkol; 1996; 42(4):32-5. PubMed ID: 8928455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma].
    Iakovleva SV; Andreeva NE; Izgorodin AS
    Ter Arkh; 1995; 67(7):35-9. PubMed ID: 7482303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum thymidine kinase and beta-2 microglobulin in monoclonal gammopathies.
    Ucci G; Riccardi A; Luoni R; Spriano P; Merlini G; Danova M; Cassano E; Molinari E; Ascari E
    Tumori; 1987 Oct; 73(5):445-9. PubMed ID: 3318049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in multiple myeloma.
    Kyle RA
    Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.